Recro Pharma Inc. (NASDAQ: REPH) Attends 31st Annual ROTH Conference
Recro Pharma (NASDAQ: REPH) is a specialty pharmaceutical company focused on products for hospitals and ambulatory care settings currently developing non-opioid products for the treatment of acute pain. The company’s lead product candidate is a proprietary injectable form of meloxicam. Intravenous (IV), meloxicam has successfully completed multiple phase 2 clinical trials for the treatment of moderate to severe pain. Recro believes injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. For more information, visit the company's website at www.recropharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and…







